Szemerédi, N.; Schelz, Z.; Horvath, D.A.; Rácz, B.; Szatmári, A.G.; Muddather, H.F.; Bózsity, N.; Zupkó, I.; Spengler, G.
Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. Pharmaceutics 2024, 16, 877.
https://doi.org/10.3390/pharmaceutics16070877
AMA Style
Szemerédi N, Schelz Z, Horvath DA, Rácz B, Szatmári AG, Muddather HF, Bózsity N, Zupkó I, Spengler G.
Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. Pharmaceutics. 2024; 16(7):877.
https://doi.org/10.3390/pharmaceutics16070877
Chicago/Turabian Style
Szemerédi, Nikoletta, Zsuzsanna Schelz, Dária Antónia Horvath, Bálint Rácz, András G. Szatmári, Hiba F. Muddather, Noémi Bózsity, István Zupkó, and Gabriella Spengler.
2024. "Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines" Pharmaceutics 16, no. 7: 877.
https://doi.org/10.3390/pharmaceutics16070877
APA Style
Szemerédi, N., Schelz, Z., Horvath, D. A., Rácz, B., Szatmári, A. G., Muddather, H. F., Bózsity, N., Zupkó, I., & Spengler, G.
(2024). Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines. Pharmaceutics, 16(7), 877.
https://doi.org/10.3390/pharmaceutics16070877